U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06874010) titled 'A Multiple Ascending Dose Study of DT-216P2 in Patients with Friedreich's Ataxia' on Feb. 25.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Friedreich Ataxia
Intervention:
DRUG: DT-216P2
Active
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Design Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....